- Home
- APLT vs OTLK Comparison
APLT vs OTLK Comparison
Compare APLT & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- OTLK
- Stock Information
- Founded
- APLT 2016
- OTLK 2010
- Country
- APLT United States
- OTLK United States
- Employees
- APLT N/A
- OTLK N/A
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- APLT Health Care
- OTLK Health Care
- Exchange
- APLT Nasdaq
- OTLK Nasdaq
- Market Cap
- APLT 44.0M
- OTLK 48.3M
- IPO Year
- APLT 2019
- OTLK 2016
- Fundamental
- Price
- APLT $0.45
- OTLK $1.96
- Analyst Decision
- APLT Buy
- OTLK Strong Buy
- Analyst Count
- APLT 7
- OTLK 5
- Target Price
- APLT $6.10
- OTLK $9.60
- AVG Volume (30 Days)
- APLT 1.6M
- OTLK 875.2K
- Earning Date
- APLT 08-11-2025
- OTLK 08-13-2025
- Dividend Yield
- APLT N/A
- OTLK N/A
- EPS Growth
- APLT N/A
- OTLK N/A
- EPS
- APLT N/A
- OTLK 0.83
- Revenue
- APLT $265,000.00
- OTLK N/A
- Revenue This Year
- APLT $415.60
- OTLK N/A
- Revenue Next Year
- APLT $1,323.96
- OTLK $419.06
- P/E Ratio
- APLT N/A
- OTLK $2.36
- Revenue Growth
- APLT N/A
- OTLK N/A
- 52 Week Low
- APLT $0.30
- OTLK $0.87
- 52 Week High
- APLT $10.62
- OTLK $8.32
- Technical
- Relative Strength Index (RSI)
- APLT 53.55
- OTLK 48.67
- Support Level
- APLT $0.46
- OTLK $1.92
- Resistance Level
- APLT $0.54
- OTLK $2.14
- Average True Range (ATR)
- APLT 0.05
- OTLK 0.16
- MACD
- APLT -0.00
- OTLK -0.03
- Stochastic Oscillator
- APLT 53.66
- OTLK 7.55
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.